• DiscoveryProbe Protease Inhibitor Library: Applied Workflows

  2026-06-19

  The DiscoveryProbe™ Protease Inhibitor Library empowers high-throughput, reproducible modulation of protease activity for advanced research in cancer, apoptosis, and infectious disease. This article details experimental workflows, troubleshooting tips, and protocol parameters that elevate screening outcomes beyond conventional libraries.

• A 83-01 (ALK-5 Inhibitor): Advanced Insights for Stem Cell a

  2026-06-18

  Explore how A 83-01, a potent ALK-5 inhibitor, is revolutionizing TGF-β signaling pathway studies with advanced applications in stem cell biology and hepatocyte stemness. This guide provides unique mechanistic insights and protocol strategies beyond standard organoid research.

• mRNA-LNP Programming of CAR Macrophages for Peritoneal Tumor

  2026-06-18

  This study introduces a macrophage-targeted mRNA lipid nanoparticle (mRNA-LNP) platform to reprogram macrophages into tailored CAR-Ms directly in the peritoneal cavity. The approach systematically evaluates CAR intracellular domain design, reveals mechanisms of immune activation and tumor microenvironment modulation, and demonstrates synergy with immune checkpoint inhibitors, offering new translational strategies against peritoneal metastases.

• 1-methyl Adenosine in RNA Modification and Biomarker Researc

  2026-06-17

  1-methyl Adenosine (1-methyl Ado) is a modified nucleoside pivotal in RNA modification research and biomarker discovery. The compound serves as a sensitive readout of RNA catabolism and is quantifiable by advanced UHPLC-MS/MS, supporting its role in cancer metabolism studies and disease diagnostics.

• LG 101506: Advancing RXR Modulation in Immuno-Oncology Resea

  2026-06-17

  This thought-leadership article explores how LG 101506, a high-purity RXR modulator from APExBIO, empowers translational researchers to unravel nuclear receptor signaling mechanisms that underpin immune resistance in cancer. By integrating mechanistic insight with strategic guidance, we highlight emerging approaches for targeting RXR pathways—particularly in the context of immune checkpoint biology and metabolism regulation—while referencing recent advances in triple-negative breast cancer (TNBC) immunotherapy. The article differentiates itself from typical product pages by bridging robust chemical biology with practical workflow recommendations and a forward-looking perspective on translational impact.

• Concerted In Vivo Screening Reveals TSA's Potential in PDA T

  2026-06-16

  This study pioneers a combined cell and in vivo screen to identify effective chemotherapeutic strategies for pancreatic ductal adenocarcinoma (PDA), highlighting the use of Trichostatin A (TSA) as a histone deacetylase inhibitor that both stimulates disease-relevant biomarkers and enhances the efficacy of established drugs. The findings suggest a rational framework for preclinical drug validation and underscore the growing importance of epigenetic modulation in cancer therapy.

• 1-methyl Adenosine in RNA Modification: Applied Protocols &

  2026-06-16

  1-methyl Adenosine (1-methyl Ado) is revolutionizing RNA modification research, empowering robust quantification and advanced biomarker discovery in cancer metabolism studies. Explore optimized workflows and troubleshooting strategies to maximize assay fidelity and translational relevance.

• Targeting AR and ARv7 in TNBC: EPI-001 Modulates Metastasis

  2026-06-15

  This study provides the first detailed analysis of androgen receptor (AR) and its splice variant ARv7 as prognostic biomarkers in triple-negative breast cancer (TNBC). It demonstrates that EPI-001, an androgen receptor N-terminal domain inhibitor, effectively suppresses metastatic and epithelial-to-mesenchymal transition (EMT) pathways in AR/ARv7-positive TNBC models, highlighting a potential strategy for overcoming poor prognosis linked to these markers.

• SGC-CBP30: Targeting Super-Enhancer Hijacking in LUAD

  2026-06-15

  Discover how SGC-CBP30, a potent CREBBP/EP300 bromodomain inhibitor, empowers translational researchers to interrogate super-enhancer hijacking and transcriptional coactivator dynamics in early-stage lung adenocarcinoma (LUAD). This thought-leadership article synthesizes mechanistic insights, experimental approaches, and strategic perspectives—anchored in recent landmark studies—to guide the next wave of epigenetics-driven cancer biology research.

• 3-Deazaneplanocin (DZNep): Precision Epigenetic Modulation i

  2026-06-14

  Explore how 3-Deazaneplanocin (DZNep) enables highly specific epigenetic modulation for advanced oncology research. Discover its unique mechanism, protocol insights, and practical assay strategies that distinguish it from conventional methods.

• Improving In Vitro Drug Response Assessment in Cancer Resear

  2026-06-13

  Schwartz's dissertation introduces a nuanced approach to in vitro anticancer drug evaluation by disentangling proliferative arrest from cell death through dual viability metrics. This distinction enhances experimental rigor and interpretation, enabling more precise assessment of epigenetic modulators like DNA methyltransferase inhibitors in preclinical settings.

• LG 101506: Decoding RXR Modulation for Cancer Immunity Resea

  2026-06-12

  Explore the advanced role of LG 101506 as an RXR modulator in unraveling nuclear receptor signaling and immunological checkpoints in cancer biology. This article delivers deep mechanistic insights and practical assay guidance for researchers investigating RXR pathways and immune evasion.

• 3-Deazaneplanocin (DZNep): Deep-Dive into Epigenetic Modulat

  2026-06-12

  Explore the science and application of 3-Deazaneplanocin (DZNep) as a potent epigenetic modulator, with fresh insights into its dual mechanism, advanced assay protocols, and relevance for cancer stem cell targeting. This article offers a distinct, in-depth analysis bridging molecular innovation to practical oncology workflows.

• Trichostatin A (TSA): Protocols and Advances in Epigenetic C

  2026-06-11

  Trichostatin A (TSA) stands at the forefront of epigenetic research, enabling precise modulation of histone acetylation for mechanistic and translational oncology studies. This guide delivers hands-on protocol tips, advanced troubleshooting, and strategic insight for deploying TSA in workflows that demand both rigor and reproducibility.

• N6-Methyl-dATP (B8093): Reliable Epigenetic Probe for Cell A

  2026-06-11

  This article provides a scenario-driven, evidence-based guide for biomedical researchers and laboratory scientists using N6-Methyl-dATP (SKU B8093). It addresses practical workflow challenges in DNA replication fidelity and epigenetic modification studies, highlighting how APExBIO’s high-purity solution enhances reproducibility and interpretability in cell viability and proliferation assays.

11535 records 1/769 page Next 12345 下5页 Last page